Nirsevimab-Alip

Introduction Overview

Generic Name

nirsevimab-alip

Brand Name

Beyfortus

Dosage Form

single-dose prefilled syringe for intramuscular injection (50 mg/0.5 mL, 100 mg/mL)

Drug Class

Antiviral monoclonal antibodies

Pharmacokinetics

Absorption

Following intramuscular administration, nirsevimab-alip (Beyfortus) is absorbed steadily into the systemic circulation, achieving protective serum concentrations rapidly to confer passive immunity against RSV. Intramuscular administration ensures high bioavailability, with absorption influenced by injection site perfusion and muscle mass, typically the upper thigh in infants. The absorption profile supports immediate protective effects against RSV during the critical first RSV season.

Distribution

Nirsevimab-alip demonstrates a distribution pattern consistent with monoclonal antibodies, primarily remaining in vascular and extracellular compartments. Due to its large molecular size, the volume of distribution approximates plasma and interstitial fluid volumes, ensuring effective circulating levels to neutralize RSV virions. Tissue penetration into the respiratory mucosa is crucial for neutralizing the virus at the site of infection. Binding to the RSV F protein on viral particles facilitates its targeted action without widespread tissue distribution.

Metabolism

As a monoclonal antibody, nirsevimab-alip is catabolized by proteolytic enzymes via reticuloendothelial system pathways, primarily in the liver and peripheral tissues. This catabolism follows typical protein degradation routes without involvement of cytochrome P450 enzymes, minimizing drug-drug metabolic interactions. The metabolic clearance rate is relatively slow, supporting its extended half-life and thereby prolonged duration of protection against RSV infection.

Elimination

Elimination of nirsevimab-alip occurs through proteolytic degradation of the antibody into small peptides and amino acids, which are then recycled or excreted. The elimination half-life supports protection lasting approximately five months after a single intramuscular dose, aligning with the typical RSV season duration. Renal or hepatic excretion of intact antibody is minimal; thus, elimination is not notably affected by renal or hepatic impairment. This pharmacokinetic profile allows for single-dose administration providing season-long protection.

Dosage Forms

Adults

Beyfortus is not indicated for adult use as it is targeted for infants and young children at risk of RSV infection.

Adolescents

Beyfortus is not indicated for adolescents; however, children up to 24 months of age who remain at risk may be administered dosing per pediatric recommendations.

Special Populations

Neonates and infants under 1 year born during or entering their first RSV season: dosing is weight-based with 50 mg intramuscular for those <5 kg and 100 mg for those ≥5 kg, given as a single injection. Children up to 24 months who remain vulnerable through their second RSV season receive 200 mg divided as two 100 mg intramuscular injections. No dose adjustments are recommended based on renal or hepatic function given monoclonal antibody elimination pathways. The drug is not studied nor recommended for children older than 24 months or adults. Administration timing prioritizes pre-season or early-season injection to ensure maximal protection during peak RSV prevalence (November through April). Available Dosage Forms: - Single-dose prefilled syringe with 50 mg/0.5 mL concentration - Single-dose prefilled syringe with 100 mg/mL concentration (1 mL)

Mechanism Of Action

Nirsevimab-alip, the active component of Beyfortus, is a recombinant human monoclonal antibody that specifically binds to the prefusion conformation of the respiratory syncytial virus (RSV) fusion (F) protein. The F protein is critical for viral entry into host respiratory epithelial cells because it mediates membrane fusion facilitating viral penetration. By binding the F protein, nirsevimab effectively blocks the conformational changes required for this fusion process, preventing RSV from infecting the cells.

This targeted binding neutralizes the virus, inhibiting viral replication and spread within the respiratory tract. The antibody’s high affinity for a conserved epitope on the F protein confers broad protection against both RSV subtypes (A and B), including strains responsible for pediatric infections. The design focuses on passive immunity, providing immediate neutralizing antibodies rather than waiting for active immune response development as in vaccination.

Clinically, this mechanism translates into effective prevention of RSV lower respiratory tract infections in vulnerable infants and toddlers during RSV season. Since nirsevimab is administered intramuscularly, it enters systemic circulation and diffuses to respiratory mucosa where infection commonly initiates. This confers rapid and lasting protection, typically for around five months, covering the full RSV season.

Compared with other monoclonal antibodies such as palivizumab, nirsevimab-alip exhibits an extended half-life due to Fc region modifications that enhance neonatal Fc receptor binding, prolonging systemic persistence. This allows single-dose administration instead of monthly dosing, improving adherence and coverage in at-risk pediatric populations. The antibody does not elicit active immune memory but provides immediate passive immunity effective in early infancy when the immune system is immature.

Pharmacological Actions

Neutralization of respiratory syncytial virus (RSV) by targeting the prefusion F protein.
Inhibition of viral entry into host respiratory epithelial cells.
Prevention of RSV replication and lower respiratory tract infection.
Provision of passive immunity in neonates and infants.
Extended half-life monoclonal antibody for prolonged protection.
Reduction of medically attended RSV infections, hospitalizations, and severe disease.
Limited systemic distribution consistent with monoclonal antibody pharmacokinetics.
No significant metabolism via cytochrome P450 enzymes, reducing drug-drug interactions.

Therapeutic Clinical Uses

Prevention of RSV lower respiratory tract disease in neonates and infants under 1 year of age during or entering their first RSV season.
Protection of children up to 24 months who remain at risk of severe RSV disease through their second RSV season.
Reduction of RSV-related medically attended infections in healthy late preterm and term infants.
Reduction of RSV-associated hospitalizations and very severe infections.
Passive immunization for infants where active vaccination is not available or less effective.
Use in both healthy and high-risk infant populations to decrease RSV disease burden.

Side Or Adverse Effects

Injection site reactions including pain, swelling, and induration.
Rash occurring post-injection.
Serious allergic reactions including anaphylaxis.
Hypersensitivity reactions such as severe rash, hives (urticaria), and itching.
Potential muscle weakness or loss of muscle tone (infantile hypotonia) in rare hypersensitivity.
Bluish discoloration of skin, lips, or under fingernails indicating possible severe reaction.
Possible respiratory symptoms – difficulty breathing or swallowing.
Local inflammation at injection site.
General tolerance profile favorable with rare serious adverse events reported.

Precautions

Avoid administration if a history of serious allergic reaction to nirsevimab-alip or any component of Beyfortus is documented.
Monitor for signs of hypersensitivity or anaphylaxis post-injection, particularly in infants with prior allergic reactions.
Use cautiously in infants with bleeding or bruising disorders due to intramuscular injection risks.
Consider timing carefully before or during the RSV season to maximize benefit.
Inform healthcare providers about any recent administration of other monoclonal antibodies for RSV, such as palivizumab.
Do not administer simultaneously in the same syringe or vial with other vaccines; however, co-administration at different sites is allowed.
Unknown safety and efficacy in children older than 24 months; avoid use outside approved age indication.
Ensure caregivers aware of signs of allergic reaction and to seek immediate medical attention if needed.

Warnings

Risk of serious allergic reactions including anaphylaxis; emergency management should be available at administration site.
Not established as safe or effective in children older than 24 months.
Potential for injection site reactions such as pain, swelling, and induration.
Monitor infants closely following injection, especially those with prior allergic histories.
Do not mix Beyfortus with other vaccines or medications in the same syringe or vial.
The product provides passive immunity and does not replace active RSV vaccination where available.
The protective effect duration is approximately 5 months; re-dosing may be necessary in prolonged risk periods.
Potential rare but serious hypersensitivity events require vigilance during and after administration.

Contraindications

Known hypersensitivity or serious allergic reaction to nirsevimab-alip or any of the inactive components of Beyfortus injection.
History of previous severe allergic reaction to Beyfortus.
Not indicated and not recommended for children older than 24 months of age.
Avoid use if the infant has an active RSV infection at the time of planned administration.
Contraindicated if there is a known severe reaction to other monoclonal antibodies with similar components without medical advice.

Drug Interactions

Concurrent or recent administration of other monoclonal antibodies against RSV such as palivizumab may interfere with efficacy or safety.
Potential interactions with anticoagulants (e.g., heparin, warfarin) require clinical assessment prior to intramuscular injection to minimize bleeding risk.
No significant drug interactions via cytochrome P450 pathways due to monoclonal antibody metabolism.
Coadministration with routine childhood vaccines is permitted at different injection sites without reduced efficacy or increased adverse events.
No data suggests interactions with vitamins, herbal supplements, or over-the-counter medications, but disclosure to healthcare provider is recommended.
Avoid mixing Beyfortus in the same syringe or vial with other vaccines or medications.

Preparations Of The Drug

Single-dose prefilled syringes available in 50 mg/0.5 mL concentration.
Single-dose prefilled syringes available in 100 mg/mL concentration (1 mL).
Sterile, preservative-free aqueous formulations.
Supplied for intramuscular injection use only.
Prefilled syringes designed for ease of administration in infants.
Packages include instructions for storage and handling per manufacturer guidelines.
Not combined with any other vaccines or medication in formulations.
Manufactured by AstraZeneca AB, distributed by Sanofi Pasteur, Inc.